{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:44:13Z","timestamp":1787021053448,"version":"build-2736575974"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Time to deterioration (TTD) endpoints are often utilized in the analysis of patient-reported outcome (PRO) data in oncology clinical trials but different endpoint definitions and analysis frameworks exist that can impact result interpretation. This review examined the analysis, reporting and heterogeneity of TTD endpoints in the literature, the impact of analysis methods on results, and provides recommendations for future trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A targeted literature review of articles published between 2017 and 2022 was performed to collate TTD endpoints reported in oncology randomized controlled trials (RCTs). Details of endpoints and results were extracted including; deterioration definition, PRO assessment schedule, methods for handling intercurrent events, statistical analysis methods, main trial results (overall survival and\/or progression-free survival) and TTD endpoint results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seventy RCTs were included covering 849 individual TTD endpoints. There were 17 primary cancer types, with lung (26%), breast (11%), and prostate (7%) cancers the most common. Most trials (71%) were for people with advanced cancer. Full definitions of TTD endpoints were often missing. There were no clear trends for a specific TTD definition within cancer types or stages. However, statistical analysis methods were consistent among trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The TTD definition can vary and is ultimately driven by the research question. Points to consider for successfully implementing PRO TTD endpoints in oncology include consideration of the trial setting (e.g., early vs. advanced cancer), expected treatment effect (e.g., improvement vs. worsening), likely adverse event profile (including early vs. delayed) and PRO data collection frequency in order to improve utility of these endpoints.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41687-024-00824-7","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T12:51:55Z","timestamp":1734526315000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Time to deterioration of patient-reported outcome endpoints in cancer clinical trials: targeted literature review and best practice recommendations"],"prefix":"10.1186","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2595-708X","authenticated-orcid":false,"given":"Kim","family":"Cocks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bellinda L.","family":"King-Kallimanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Sims","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gill","family":"Worthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Ayala\u2013Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Achra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanglin Lin","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nalin","family":"Payakachat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"issue":"6","key":"824_CR1","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s40258-023-00827-3","volume":"21","author":"M Meregaglia","year":"2023","unstructured":"Meregaglia M, Malandrini F, Angelini S, Ciani O (2023) The assessment of patient-reported outcomes for the authorisation of medicines in Europe: a review of European Public Assessment Reports from 2017 to 2022. Appl Health Econ Health Policy 21(6):925\u2013935","journal-title":"Appl Health Econ Health Policy"},{"key":"824_CR2","unstructured":"Food and Drug Administration (FDA) Enhancing the incorporation of the patient\u2019s voice in medical product development and regulatory decision making. https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-patients-voice-medical"},{"issue":"29","key":"824_CR3","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.2217\/fon-2022-0374","volume":"18","author":"O Chassany","year":"2022","unstructured":"Chassany O, Engen A, Lai L et al (2022) A call to action to harmonize patient-reported outcomes evidence requirements across key European HTA bodies in oncology. Future Oncol 18(29):3323\u20133334","journal-title":"Future Oncol"},{"issue":"5","key":"824_CR4","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1093\/neuonc\/not236","volume":"16","author":"K Han","year":"2014","unstructured":"Han K, Ren M, Wick W et al (2014) Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials. Neuro-oncology 16(5):696\u2013706","journal-title":"Neuro-oncology"},{"issue":"3","key":"824_CR5","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3747\/co.22.2119","volume":"22","author":"C Beauchemin","year":"2015","unstructured":"Beauchemin C, Johnston J, Lapierre M, Aissa F, Lachaine J (2015) Relationship between progression-free survival and overall survival in chronic lymphocytic leukemia: a literature-based analysis. Current Oncol 22(3):148\u2013156","journal-title":"Current Oncol"},{"key":"824_CR6","unstructured":"Food and Drug Administration (FDA) (2018) Clinical trial endpoints for the approval of cancer drugs and biologics - guidance for industry"},{"issue":"5","key":"824_CR7","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.clgc.2019.07.007","volume":"17","author":"L Marandino","year":"2019","unstructured":"Marandino L, De Luca E, Zichi C et al (2019) Quality-of-life assessment and reporting in prostate cancer: systematic review of phase 3 trials testing anticancer drugs published between 2012 and 2018. Clin Genitourin Cancer 17(5):332\u2013347.e2","journal-title":"Clin Genitourin Cancer"},{"issue":"7","key":"824_CR8","first-page":"1","volume":"23","author":"S Kilickap","year":"2018","unstructured":"Kilickap S, Demirci U, Karadurmus N, Dogan M, Akinci B, Sendur MAN (2018) Endpoints in oncology clinical trials. J Buon 23(7):1\u20136","journal-title":"J Buon"},{"issue":"8","key":"824_CR9","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1586\/14737140.2015.1047768","volume":"15","author":"F Fiteni","year":"2015","unstructured":"Fiteni F, Pam A, Anota A et al (2015) Health-related quality-of-life as co-primary endpoint in randomized clinical trials in oncology. Expert Rev Anticancer Ther 15(8):885\u2013891","journal-title":"Expert Rev Anticancer Ther"},{"issue":"10","key":"824_CR10","doi-asserted-by":"publisher","first-page":"e582","DOI":"10.1016\/S1470-2045(19)30335-3","volume":"20","author":"MH Fiero","year":"2019","unstructured":"Fiero MH, Roydhouse JK, Vallejo J, King-Kallimanis BL, Kluetz PG, Sridhara R (2019) US Food and Drug Administration review of statistical analysis of patient-reported outcomes in lung cancer clinical trials approved between January, 2008, and December, 2017. Lancet Oncol 20(10):e582\u2013e589. https:\/\/doi.org\/10.1016\/S1470-2045(19)30335-3","journal-title":"Lancet Oncol"},{"issue":"1","key":"824_CR11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11136-013-0583-6","volume":"24","author":"A Anota","year":"2015","unstructured":"Anota A, Hamidou Z, Paget-Bailly S et al (2015) Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization? Qual Life Res 24(1):5\u201318","journal-title":"Qual Life Res"},{"key":"824_CR12","unstructured":"Machingura A, Coens C, Pe M et al. Methodological work and use of patient-reported outcomes data in Randomised Controlled Trials (Rcts) in cancer: literature reviews on current practices and guidelines"},{"key":"824_CR13","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2147\/PROM.S156279","volume":"9","author":"R Mercieca-Bebber","year":"2018","unstructured":"Mercieca-Bebber R, King MT, Calvert MJ, Stockler MR, Friedlander M (2018) The importance of patient-reported outcomes in clinical trials and strategies for future optimization. Patient Relat Outcome Meas 9:353\u2013367","journal-title":"Patient Relat Outcome Meas"},{"issue":"4","key":"824_CR14","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s11136-019-02367-7","volume":"29","author":"E Charton","year":"2020","unstructured":"Charton E, Cuer B, Cottone F et al (2020) Time to deterioration in cancer randomized clinical trials for patient-reported outcomes data: a systematic review. Qual Life Res 29(4):867\u2013878","journal-title":"Qual Life Res"},{"issue":"1","key":"824_CR15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s11136-020-02605-3","volume":"30","author":"C Bascoul-Mollevi","year":"2021","unstructured":"Bascoul-Mollevi C, Barbieri A, Bourgier C et al (2021) Longitudinal analysis of health-related quality of life in cancer clinical trials: methods and interpretation of results. Qual Life Res 30(1):91\u2013103","journal-title":"Qual Life Res"},{"issue":"5","key":"824_CR16","doi-asserted-by":"publisher","first-page":"e229","DOI":"10.1016\/S1470-2045(22)00021-3","volume":"23","author":"MH Fiero","year":"2022","unstructured":"Fiero MH, Roydhouse JK, Bhatnagar V et al (2022) Time to deterioration of symptoms or function using patient-reported outcomes in cancer trials. Lancet Oncol 23(5):e229\u2013e234","journal-title":"Lancet Oncol"},{"key":"824_CR17","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"issue":"4","key":"824_CR18","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.jtho.2020.12.019","volume":"16","author":"M Reck","year":"2021","unstructured":"Reck M, Ciuleanu T-E, Lee J-S et al (2021) First-line nivolumab plus ipilimumab versus chemotherapy in advanced NSCLC with 1% or greater tumor PD-L1 expression: patient-reported outcomes from CheckMate 227 Part 1. J Thorac Oncol 16(4):665\u2013676","journal-title":"J Thorac Oncol"},{"issue":"4","key":"824_CR19","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1200\/JCO.21.00601","volume":"40","author":"A Adenis","year":"2022","unstructured":"Adenis A, Kulkarni AS, Girotto GC et al (2022) Impact of pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer on health-related quality of life in KEYNOTE-181. J Clin Oncol 40(4):382\u2013391","journal-title":"J Clin Oncol"},{"issue":"4","key":"824_CR20","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.eururo.2022.06.009","volume":"82","author":"J Bedke","year":"2022","unstructured":"Bedke J, Rini BI, Plimack ER et al (2022) Health-related quality of life analysis from KEYNOTE-426: pembrolizumab plus axitinib versus sunitinib for advanced renal cell carcinoma. Eur Urol 82(4):427\u2013439","journal-title":"Eur Urol"},{"issue":"2","key":"824_CR21","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/S1470-2045(21)00693-8","volume":"23","author":"D Cella","year":"2022","unstructured":"Cella D, Motzer RJ, Suarez C et al (2022) Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial. Lancet Oncol 23(2):292\u2013303","journal-title":"Lancet Oncol"},{"issue":"4","key":"824_CR22","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.cllc.2021.02.010","volume":"22","author":"EB Garon","year":"2021","unstructured":"Garon EB, Cho BC, Reinmuth N et al (2021) Patient-reported outcomes with durvalumab with or without tremelimumab versus standard chemotherapy as first-line treatment of metastatic non\u2013small-cell lung cancer (MYSTIC). Clin Lung Cancer 22(4):301\u2013312.e8","journal-title":"Clin Lung Cancer"},{"issue":"18","key":"824_CR23","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1200\/JCO.2017.77.2293","volume":"36","author":"CK Lee","year":"2018","unstructured":"Lee CK, Novello S, Ryd\u00e9n A et al (2018) Patient-reported symptoms and impact of treatment with osimertinib versus chemotherapy in advanced non-small-cell lung cancer: the AURA3 trial. J Clin Oncol 36(18):1853\u20131860","journal-title":"J Clin Oncol"},{"issue":"11","key":"824_CR24","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1158\/1078-0432.CCR-19-2838","volume":"26","author":"MB Atkins","year":"2020","unstructured":"Atkins MB, Rini BI, Motzer RJ et al (2020) Patient-reported outcomes from the Phase III randomized IMmotion151 trial: atezolizumab+ Bevacizumab versus sunitinib in treatment-na\u00efve metastatic renal cell CarcinomaIMmotion151 PROs with Atezolizumab plus Bevacizumab in mRCC. Clin Cancer Res 26(11):2506\u20132514","journal-title":"Clin Cancer Res"},{"key":"824_CR25","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.lungcan.2019.05.009","volume":"133","author":"A Morabito","year":"2019","unstructured":"Morabito A, Piccirillo MC, Maione P et al (2019) Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer: joint analysis of MILES-3 and MILES-4 randomised phase 3 trials. Lung Cancer 133:62\u201368","journal-title":"Lung Cancer"},{"key":"824_CR26","doi-asserted-by":"crossref","unstructured":"Van Cutsem E, Kato K, Ajani JA et al (2022) Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): impact on health-related quality of life (HRQoL). Am Soc Clin Oncol","DOI":"10.1016\/j.esmoop.2022.100517"},{"issue":"8","key":"824_CR27","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1200\/JCO.18.00050","volume":"37","author":"J Edeline","year":"2019","unstructured":"Edeline J, Benabdelghani M, Bertaut A et al (2019) Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. J Clin Oncol 37(8):658\u2013667","journal-title":"J Clin Oncol"},{"issue":"5","key":"824_CR28","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.cllc.2018.05.011","volume":"19","author":"R Bordoni","year":"2018","unstructured":"Bordoni R, Ciardiello F, von Pawel J et al (2018) Patient-reported outcomes in OAK: a phase III study of atezolizumab versus docetaxel in advanced non\u2013small-cell lung cancer. Clin Lung Cancer 19(5):441\u2013449.e4","journal-title":"Clin Lung Cancer"},{"issue":"5","key":"824_CR29","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S1470-2045(21)00064-4","volume":"22","author":"T Andre","year":"2021","unstructured":"Andre T, Amonkar M, Norquist JM et al (2021) Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial. Lancet Oncol 22(5):665\u2013677","journal-title":"Lancet Oncol"},{"issue":"7","key":"824_CR30","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1093\/neuonc\/noab011","volume":"23","author":"JS Wefel","year":"2021","unstructured":"Wefel JS, Armstrong TS, Pugh SL et al (2021) Neurocognitive, symptom, and health-related quality of life outcomes of a randomized trial of bevacizumab for newly diagnosed glioblastoma (NRG\/RTOG 0825). Neuro-oncology 23(7):1125\u20131138","journal-title":"Neuro-oncology"},{"issue":"4","key":"824_CR31","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/jamaoncol.2017.5082","volume":"4","author":"MJ Taphoorn","year":"2018","unstructured":"Taphoorn MJ, Dirven L, Kanner AA et al (2018) Influence of treatment with tumor-treating fields on health-related quality of life of patients with newly diagnosed glioblastoma: a secondary analysis of a randomized clinical trial. JAMA Oncol 4(4):495\u2013504","journal-title":"JAMA Oncol"},{"issue":"10","key":"824_CR32","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.jtho.2018.06.012","volume":"13","author":"Y-L Wu","year":"2018","unstructured":"Wu Y-L, Lu S, Lu Y et al (2018) Results of PROFILE 1029, a phase III comparison of first-line crizotinib versus chemotherapy in East Asian patients with ALK-positive advanced non\u2013small cell lung cancer. J Thorac Oncol 13(10):1539\u20131548","journal-title":"J Thorac Oncol"},{"issue":"11","key":"824_CR33","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/S1470-2045(19)30620-5","volume":"20","author":"N Agarwal","year":"2019","unstructured":"Agarwal N, McQuarrie K, Bjartell A et al (2019) Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. Lancet Oncol 20(11):1518\u20131530","journal-title":"Lancet Oncol"},{"issue":"25","key":"824_CR34","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1200\/JCO.2018.78.5865","volume":"36","author":"J Strosberg","year":"2018","unstructured":"Strosberg J, Wolin E, Chasen B et al (2018) Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with 177Lu-dotatate in the phase III NETTER-1 trial. J Clin Oncol 36(25):2578","journal-title":"J Clin Oncol"},{"key":"824_CR35","doi-asserted-by":"publisher","first-page":"5523","DOI":"10.2147\/CMAR.S305939","volume":"13","author":"R-D Hofheinz","year":"2021","unstructured":"Hofheinz R-D, Bruix J, Demetri GD et al (2021) Effect of regorafenib in delaying definitive deterioration in health-related quality of life in patients with advanced cancer of three different tumor types. Cancer Manage Res 13:5523","journal-title":"Cancer Manage Res"},{"key":"824_CR36","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.lungcan.2019.10.002","volume":"138","author":"M P\u00e9rol","year":"2019","unstructured":"P\u00e9rol M, Pavlakis N, Levchenko E et al (2019) Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer. Lung Cancer 138:79\u201387","journal-title":"Lung Cancer"},{"issue":"2","key":"824_CR37","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.clml.2020.09.003","volume":"21","author":"P Porcu","year":"2021","unstructured":"Porcu P, Hudgens S, Horwitz S et al (2021) Quality of life effect of the anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat in patients with cutaneous T-cell lymphoma. Clin Lymphoma Myeloma Leukemia 21(2):97\u2013105","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"824_CR38","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.lungcan.2021.03.005","volume":"155","author":"MRG Campelo","year":"2021","unstructured":"Campelo MRG, Lin HM, Zhu Y et al (2021) Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor\u2013naive ALK+ non\u2212 small cell lung cancer (ALTA-1L). Lung Cancer 155:68\u201377","journal-title":"Lung Cancer"},{"key":"824_CR39","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.lungcan.2020.09.003","volume":"149","author":"JW Goldman","year":"2020","unstructured":"Goldman JW, Garassino MC, Chen Y et al (2020) Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study. Lung Cancer 149:46\u201352","journal-title":"Lung Cancer"},{"key":"824_CR40","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.lungcan.2022.03.012","volume":"167","author":"A Scherpereel","year":"2022","unstructured":"Scherpereel A, Antonia S, Bautista Y et al (2022) First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743. Lung Cancer 167:8\u201316","journal-title":"Lung Cancer"},{"issue":"6","key":"824_CR41","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/S1470-2045(22)00212-1","volume":"23","author":"R Motzer","year":"2022","unstructured":"Motzer R, Porta C, Alekseev B et al (2022) Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study. Lancet Oncol 23(6):768\u2013780","journal-title":"Lancet Oncol"},{"key":"824_CR42","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejca.2019.11.006","volume":"125","author":"NB Leighl","year":"2020","unstructured":"Leighl NB, Karaseva N, Nakagawa K et al (2020) Patient-reported outcomes from FLAURA: osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer. Eur J Cancer 125:49\u201357","journal-title":"Eur J Cancer"},{"issue":"2","key":"824_CR43","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s10549-021-06217-4","volume":"188","author":"B Moy","year":"2021","unstructured":"Moy B, Oliveira M, Saura C et al (2021) Neratinib+ capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and\u2265 2 prior HER2-directed regimens. Breast Cancer Res Treat 188(2):449\u2013458","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"824_CR44","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.ijrobp.2021.01.032","volume":"110","author":"S Roy","year":"2021","unstructured":"Roy S, Grimes S, Morgan SC et al (2021) Patient-reported outcomes from a phase 3 randomized controlled trial exploring optimal sequencing of short-term androgen deprivation therapy with prostate radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 110(4):1101\u20131113","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"824_CR45","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S2468-1253(21)00110-2","volume":"6","author":"A Vogel","year":"2021","unstructured":"Vogel A, Qin S, Kudo M et al (2021) Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol 6(8):649\u2013658","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"11","key":"824_CR46","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1158\/1078-0432.CCR-21-3530","volume":"28","author":"M Majem","year":"2022","unstructured":"Majem M, Goldman JW, John T et al (2022) Health-related quality of life outcomes in patients with resected epidermal growth factor receptor\u2013mutated non\u2013small cell lung cancer who received adjuvant osimertinib in the Phase III ADAURA trial. Clin Cancer Res 28(11):2286\u20132296","journal-title":"Clin Cancer Res"},{"issue":"4","key":"824_CR47","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/S1470-2045(18)30898-2","volume":"20","author":"B Tombal","year":"2019","unstructured":"Tombal B, Saad F, Penson D et al (2019) Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 20(4):556\u2013569","journal-title":"Lancet Oncol"},{"issue":"4","key":"824_CR48","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.eururo.2022.04.016","volume":"83","author":"P Grivas","year":"2022","unstructured":"Grivas P, Kopyltsov E, Su P-J et al (2022) Patient-reported outcomes from JAVELIN Bladder 100: avelumab first-line maintenance plus best supportive care versus best supportive care alone for advanced urothelial carcinoma. Eur Urol 83(4):320\u2013328","journal-title":"Eur Urol"},{"issue":"2","key":"824_CR49","doi-asserted-by":"publisher","first-page":"e243","DOI":"10.1634\/theoncologist.2019-0551","volume":"25","author":"PA Kaufman","year":"2020","unstructured":"Kaufman PA, Toi M, Neven P et al (2020) Health-related quality of life in MONARCH 2: abemaciclib plus fulvestrant in hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy. Oncologist 25(2):e243\u2013e251","journal-title":"Oncologist"},{"issue":"1","key":"824_CR50","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s40261-020-00979-3","volume":"41","author":"K Yamaguchi","year":"2021","unstructured":"Yamaguchi K, Shimada Y, Hironaka S et al (2021) Quality of life associated with ramucirumab treatment in patients with advanced gastric cancer in Japan: exploratory analysis from the Phase III RAINBOW trial. Clin Drug Invest 41(1):53\u201364","journal-title":"Clin Drug Invest"},{"issue":"10","key":"824_CR51","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1080\/03007995.2020.1808781","volume":"36","author":"K Yoh","year":"2020","unstructured":"Yoh K, Atagi S, Reck M et al (2020) Patient-reported outcomes in RELAY, a phase 3 trial of ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small-cell lung cancer. Curr Med Res Opin 36(10):1667\u20131675","journal-title":"Curr Med Res Opin"},{"key":"824_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2022.03.027","volume":"169","author":"J Li","year":"2022","unstructured":"Li J, Cheng Y, Bai C et al (2022) Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep). Eur J Cancer 169:1\u20139","journal-title":"Eur J Cancer"},{"issue":"8","key":"824_CR53","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/S1470-2045(17)30421-7","volume":"18","author":"KJ Harrington","year":"2017","unstructured":"Harrington KJ, Ferris RL, Blumenschein Jr G et al (2017) Nivolumab versus standard, single-agent therapy of investigator\u2019s choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol 18(8):1104\u20131115","journal-title":"Lancet Oncol"},{"issue":"5","key":"824_CR54","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.euo.2022.02.003","volume":"5","author":"JA Witjes","year":"2022","unstructured":"Witjes JA, Galsky MD, Gschwend JE et al (2022) Health-related quality of life with adjuvant nivolumab after radical resection for high-risk muscle-invasive urothelial carcinoma: results from the phase 3 CheckMate 274 trial. Eur Urol Oncol 5(5):553\u2013563","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"824_CR55","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2307\/2529620","volume":"30","author":"N Breslow","year":"1974","unstructured":"Breslow N (1974) Covariance analysis of censored survival data. Biometrics 30(1):89\u201399","journal-title":"Biometrics"},{"issue":"6","key":"824_CR56","doi-asserted-by":"publisher","first-page":"e045105","DOI":"10.1136\/bmjopen-2020-045105","volume":"11","author":"M Calvert","year":"2021","unstructured":"Calvert M, King M, Mercieca-Bebber R et al (2021) SPIRIT-PRO extension explanation and elaboration: guidelines for inclusion of patient-reported outcomes in protocols of clinical trials. BMJ Open 11(6):e045105. https:\/\/doi.org\/10.1136\/bmjopen-2020-045105","journal-title":"BMJ Open"},{"issue":"1","key":"824_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41687-020-00218-5","volume":"4","author":"R Lawrance","year":"2020","unstructured":"Lawrance R, Degtyarev E, Griffiths P et al (2020) What is an estimand & how does it relate to quantifying the effect of treatment on patient-reported quality of life outcomes in clinical trials? J Patient-rep Outcomes 4(1):1\u20138","journal-title":"J Patient-rep Outcomes"},{"issue":"8","key":"824_CR58","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1001\/jama.2013.879","volume":"309","author":"M Calvert","year":"2013","unstructured":"Calvert M, Blazeby J, Altman DG et al (2013) Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA 309(8):814\u2013822. https:\/\/doi.org\/10.1001\/jama.2013.879","journal-title":"JAMA"},{"key":"824_CR59","unstructured":"International Council for Harmonisation (ICH) (2020) Addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials E9 (R1). Step 5. Fed Regist 1\u201319"},{"issue":"2","key":"824_CR60","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1016\/s1470-2045(19)30790-9","volume":"21","author":"C Coens","year":"2020","unstructured":"Coens C, Pe M, Dueck AC et al (2020) International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium. Lancet Oncol 21(2):e83\u2013e96. https:\/\/doi.org\/10.1016\/s1470-2045(19)30790-9","journal-title":"Lancet Oncol"},{"key":"824_CR61","unstructured":"Novartis Pharmaceuticals Corporation (2019) Zykadia\u00ae (ceritinib) [package insert] [Internet]. U.S Food and Drug Administration website"},{"key":"824_CR62","unstructured":"European Medicines Agency (2015) Zykadia: EPAR - product information"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-024-00824-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-024-00824-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-024-00824-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T13:14:26Z","timestamp":1734527666000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpro.springeropen.com\/articles\/10.1186\/s41687-024-00824-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["824"],"URL":"https:\/\/doi.org\/10.1186\/s41687-024-00824-7","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,18]]},"assertion":[{"value":"19 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"NP is a full-time employee of Eli Lilly and Company and ZLC is an employee and a stockholder of Eli Lilly and Company. Adelphi Values received funding from Eli Lilly and Company to conduct the research.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"150"}}